SOP for Microbiological Testing of Packaging Materials

In short: This illustrative SOP template describes a possible microbiology QC approach for monitoring packaging materials. The example sample counts, test methods, incubation time, frequency, and blank limits are site proposals that need approval and method-suitability evidence before use. They are not universal pharmacopoeial limits or instructions.

Objective

Describe how a microbiology QC laboratory can sample and assess the microbial load of selected packaging materials using an approved, material-specific method.

Scope

This template covers PVC and PVDC film, plain and printed aluminium foil, polythene bags, containers, and closures. Apply the procedure only to material types included in the site’s approved specification and sampling plan. Select tests according to the material’s intended use and the risk that objectionable microbial contamination could affect the product.

Responsibilities

Example in-house criterion (not a pharmacopoeial requirement): A trained and authorised microbiology analyst performs and records the test. The Head of Microbiology ensures the method, sampling plan, acceptance criteria, equipment, and training are reviewed and approved by the appropriate quality unit before routine use.

Procedure

Pre-use approval and equipment

Before routine testing, confirm that the current approved method defines the material, supplier and lot, sampling location and quantity, sample handling, recovery method, controls, incubation conditions, calculations, and acceptance criteria. Do not execute this template with blank or unapproved fields.

For materials and closures regulated under U.S. drug CGMP, 21 CFR 211.84(a)–(b) requires lot sampling and testing or examination as appropriate, with sampling quantity based on appropriate criteria. Under §211.84(d)(6), microbiological testing is required before use when contamination could be objectionable in view of the material’s intended use. Section 211.160(a) requires laboratory specifications, sampling plans, and test procedures to be written and reviewed and approved by the quality control unit. These provisions do not provide the sample counts, method parameters, frequency, or numerical limits proposed in this example SOP.

This example SOP lists a laminar airflow workstation (LAF), colony counter, and incubators. Example in-house criterion (not a pharmacopoeial requirement): use identified, qualified equipment suitable for the approved method and the material being handled.

Candidate sampling plan

Example in-house criterion (not a pharmacopoeial requirement): This example SOP proposes discarding the first one metre of a roll and collecting the next one metre for PVC/PVDC film and plain or printed aluminium foil under an LAF workstation. It also proposes one polythene bag from each bundle and five containers. These are candidate quantities only; collect representative samples under the approved plan using aseptic techniques where needed.

Identify every sample with the material, supplier, lot or consignment, source container or roll, collection date, and sampler. Keep samples protected from contamination or mix-up during collection and transfer.

Candidate recovery methods

This example SOP proposes a contact-plate method for the accessible inner surface of films and foils, using a Replicate Organism Detection and Counting (RODAC) plate with soybean-casein digest agar (SCDA). For bags, it proposes rinsing; for containers and closures, it proposes membrane filtration of a rinse. These method assignments are examples, not a universal method for all packaging materials.

For bags, containers, and closures, this example SOP describes rinsing the complete inner surface with no more than 100 mL of sterile 0.1% peptone water for five containers, filtering the rinse through a sterile 0.45 µm membrane, and then rinsing three times with 100 mL peptone water. It does not make clear whether those additional rinses are combined, filtered separately, or included in the reported result. Do not use these quantities or sequence until the approved method resolves that ambiguity.

Controls and incubation

This example SOP proposes keeping one unused contact plate as a negative control and filtering 100 mL of sterile 0.1% peptone water as a rinse-method negative control. Run and interpret controls according to the approved method; investigate a control failure before accepting sample results.

This example SOP says to incubate plates under “favourable conditions” for five days but does not give a temperature, atmosphere, medium-specific condition, or justification for the duration. Treat five days as an unapproved proposal until the conditions are specified in a suitable method.

Frequency and acceptance criteria

Example in-house criterion (not a pharmacopoeial requirement): This example SOP says “once in a year for the first five consignments of each vendor.” This wording does not establish whether testing is annual, applies to the first five consignments, or both. Set the actual frequency in the approved risk-based plan and document how supplier history and changes affect it.

This example SOP leaves all acceptance values blank. It proposes limits in CFU per 25 cm² for foil and films and per five units for bags, containers, or closures, with separate aerobic and yeast/mould counts. Use only the approved material-specific limits and reporting units. “Total aerobic microbial count” is abbreviated TAMC; “total yeast and mould count” is a separate count and should not be labelled TAMC.

Result review and action

Record the raw count and calculation, report results using the approved sample basis, and compare them only with the currently approved material specification. Refer atypical growth, a failed control, an out-of-limit result, or a method deviation to the site’s investigation and material-disposition procedures. Do not release or reject a lot solely from this illustrative template.

Records

Example in-house criterion (not a pharmacopoeial requirement): The controlled worksheet or log should identify the material and supplier lot, sample locations and quantity, method and media or rinse details, equipment, controls, incubation conditions, observations, counts and calculation, reviewer, and any deviation or investigation reference.

Retain batch-specific GMP records at least one year after expiry of the respective product batch. Under EU GMP Part I Chapter 4 §4.11, batch documentation is retained for one year after expiry or at least five years after Qualified Person certification, whichever is longer. 21 CFR 211.180(a), current eCFR edition (2026), sets at least one year after expiry for production, control, or distribution records specifically associated with a drug-product batch. Apply any longer retention requirement from applicable law or the marketing authorisation.

Related procedures

• Sampling of packaging materials
• Approval or rejection of packaging materials
• Good microbiological laboratory practice

Frequently asked questions

Are the sample counts and CFU limits in this template mandatory?

No. They are inherited site proposals, and the limit fields are blank. A quality-approved, justified sampling plan and material-specific acceptance criteria are needed before routine testing.

Can the contact-plate and rinse methods be used without further study?

Do not assume that they are suitable for every surface or packaging design. WHO TRS 961 Annex 2 calls for method suitability for routine use and validation where a method is not based on a compendial or other recognised reference.

When is microbiological testing of packaging materials needed under U.S. CGMP?

Under 21 CFR 211.84(d)(6), test before use when a component, container, or closure has potential for microbiological contamination that could be objectionable in view of its intended use. The site’s approved specifications and test plan determine the appropriate method and criteria.

References

1. United States Electronic Code of Federal Regulations. 21 CFR §211.84(a)–(d)(6), testing and approval or rejection of components, drug product containers, and closures; and §211.160(a), laboratory control mechanisms (current eCFR edition, 2026; accessed 19 October 2026). §211.84; §211.160.
2. World Health Organization. WHO good practices for pharmaceutical microbiology laboratories, WHO Technical Report Series No. 961, Annex 2 (2011), §§3.1–3.2. Official WHO PDF.
3. European Commission. EudraLex Volume 4, EU Guidelines for Good Manufacturing Practice, Part I, Chapter 4: Documentation (January 2011), §4.11. Official PDF.
4. United States Electronic Code of Federal Regulations. 21 CFR §211.180(a), current eCFR edition (2026; accessed 19 October 2026). Official regulation.